Alberto Rizzo

Dr. Alberto Rizzo

Luigi Sacco Hospital - ASST Fatebenefratelli Sacco
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2022 in Journal of Infection
Verified
Journal Article
Closed access
ARAngelo Roberto Raccagni
Angelo Roberto Raccagni
CCCaterina Candela
Caterina Candela
DMDavide Mileto
Davide Mileto
DCDiana Canetti
Diana Canetti
EBElena Bruzzesi
Elena Bruzzesi
SNSilvia Nozza
Silvia Nozza

23 February 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
GPGabriele Pagani
Gabriele Pagani
ALAlessia Lai
Alessia Lai
ABAnnalisa Bergna
Annalisa Bergna
ARAlberto Rizzo
Alberto Rizzo
ASAngelica Stranieri
Angelica Stranieri
Gianguglielmo ZehenderGianguglielmo Zehender
Gianguglielmo Zehender
There have been previous reports of the human-to-cat transmission of SARS-CoV-2, but there are only a few molecular studies that have compared the whole genome of the virus in cats and their owners. We here describe a case of domestic SARS-CoV-2 transmission from a healthcare worker to his cat for which nasopharyngeal swabs of both the cat and its owner were used for full-genome analysis. The results indicate that quarantine measures should be extended to pets living in SARS-CoV-2-infected households.

20 October 2022 in Journal of Medical Virology
Verified
Journal Article
Closed access
ARAngelo Roberto Raccagni
Angelo Roberto Raccagni
CCCaterina Candela
Caterina Candela
EBElena Bruzzesi
Elena Bruzzesi
DMDavide Mileto
Davide Mileto
DCDiana Canetti
Diana Canetti
SNSilvia Nozza
Silvia Nozza

2 March 2023 in Viruses
Verified
Journal Article
Open access
PDF file
CCCaterina Candela
Caterina Candela
ARAngelo Roberto Raccagni
Angelo Roberto Raccagni
EBElena Bruzzesi
Elena Bruzzesi
CBCostanza Bertoni
Costanza Bertoni
ARAlberto Rizzo
Alberto Rizzo
SNSilvia Nozza
Silvia Nozza
Background: Monkeypox virus (mpxv) started to spread to Europe and North America at the beginning of the current outbreak in May 2022, and the World Health Organization (WHO) declared Human Monkeypox (mpox) as a public health emergency of international concern (PHEIC) in July 2022. The aim of this observational analysis is to describe demographical data, symptoms presentation and clinical course till outcome of individuals diagnosed with mpox, between May and October 2022, at our open-access Sexual Health Clinic in IRCCS San Raffaele Hospital in Milan, Italy. Methods: Among people who accessed our Sexual Health Clinic, we considered, as suspected diagnosis of mpox, individuals with consistent symptoms and epidemiological criteria. Following the physical examination, oropharyngeal, anal, genital and cutaneous swabs, plus plasma, urine and seminal fluid were collected as biological materials to detect mpxv DNA. We also performed a screening for sexually transmitted infections (STIs). Results: Overall, 140 individuals with mpox were included in this study. Median age was 37 (interquartile, IQR 33, 43) years old. Males were 137 (98%) and men who have sex with men (MSM) were 134 (96%). As risk factors, we detected travels abroad in 35 (25%) individuals and close contact with mpox cases in 49 (35%). There were 66 (47%) people living with HIV (PLWH). Most frequent symptoms were fever (59%), lymphadenopathy (57%), cutaneous (77%), genital (42%), anal (34%) and oral (26%) lesions, proctitis (39%), sore throat (22%) and generalized rash (5%). At mpox diagnosis, we also observed N. gonorrhoeae in 18 (13%) cases, syphilis in 14 (10%) and C. trachomatis in 12 (9%). Two (1%) people received a concomitant diagnosis of HIV infection. We attended to 21 (15%) complications, with nine (6%) cases of hospitalization including six (IQR 3,7) median hospital days. Forty-five (32%) patients were treated with non-steroidal anti-inflammatory drugs (NSAIDs), 37 (26%) with antibiotics and eight (6%) with antiviral drugs. Conclusions: Similarly to other international cohorts, sexual transmission was most frequently present, and concomitant STIs were common. Symptoms were heterogenous, self-resolving and responsive to therapy. Hospitalization was necessary in few patients. There is uncertainty about the future development of mpox and further studies (e.g., potential disease reservoirs, other possible means of transmission, predictors of severe disease) are still needed.

1 January 2021 in Emerging Microbes & Infections
Verified
Journal Article
Open access
DMDavide Mileto
Davide Mileto
CFClaudio Fenizia
Claudio Fenizia
MCM. Cutrera
M. Cutrera
GGG. Gagliardi
G. Gagliardi
AGA. Gigantiello
A. Gigantiello
ALA. Lombardi
A. Lombardi
As the SARS-CoV-2 pandemic continues to rage world-wide, the emergence of numerous variants of concern (VOC) represents a challenge for the vaccinal protective efficacy and reliability of commercially available high-throughput immunoassays. Our study demonstrates that, the administration of two doses of BNT162b2 vaccine elicited a robust SARS-CoV-2-specific immune response assessed up to three months after full vaccination in a cohort of 37 health care workers (HCWs). SARS-CoV-2 specific antibody response, evaluated by four commercially available chemiluminescence immunoassays (CLIA), was qualitatively consistent with the results provided by the gold-standard in vitro neutralization assay (NTA). However, we could not observe a correlation between the quantity of antibody detected by CLIA assays and their neutralizing activity tested by NTA. Almost all subjects developed a SARS-CoV-2 specific T cell response. Moreover, vaccinated HCWs developed a similarly protective neutralizing antibodies response against the EU (B.1), Alpha (B.1.1.7), Gamma (P.1), and Eta (B.1.525) SARS-CoV-2 variants, while Beta (B.1.351) and Delta (B.1.617.2) strains displayed a consistent partial immune evasion. These results underline the importance of a solid vaccine-elicited immune response and a robust antibody titer. We believe that these relevant results should be taken into consideration in the definition of future vaccinal strategies.

13 November 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
PSPierachille Santus
Pierachille Santus
DDDanzo Danzo
Danzo Danzo
JSJuan Camilo Signorello
Juan Camilo Signorello
ARAlberto Rizzo
Alberto Rizzo
AGAndrea Gori
Andrea Gori
DRDejan Radovanovic
Dejan Radovanovic
Which patients should be monitored for coinfections or should receive empirical antibiotic treatment, in patients with an acute viral respiratory infection, is largely unknown. We evaluated the prevalence, characteristics, outcomes of coinfected patients, and risk factors associated with a coinfection among patients with an acute viral infection. A retrospective, single-center study recruited consecutive patients from October 2022 to March 2023 presenting to the emergency department with signs of a respiratory tract infection. Patients were screened for respiratory viruses and bacterial/fungal secondary infections according to local standard procedures. Outcomes included severe disease, in-hospital complications, all-cause in-hospital and ICU-related mortality, time to death, time to discharge, and time to coinfection. The analysis included 652 patients. A viral infection and a secondary bacterial/fungal infection were detected in 39.1% and 40% of cases. Compared with the rest of the cohort, coinfected patients had more frequently severe disease (88.3%, p < 0.001; 51% in patients with SARS-CoV-2) and higher in-hospital mortality (16.5%, p = 0.010). Nephropathy (OR 3.649, p = 0.007), absence of COVID-19 vaccination (OR 0.160, p < 0.001), SARS-CoV-2 infection (OR 2.390, p = 0.017), and lower blood pressure at admission (OR 0.980, p = 0.007) were independent risk factors for coinfection. Multidrug-resistant pathogens were detected in 30.8% of all coinfections. Patients with a viral infection are at high risk of bacterial coinfections, which carry a significant morbidity and mortality burden.